A detailed history of Virtus ETF Advisers LLC transactions in Cure Vac N.V. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 23,036 shares of CVAC stock, worth $63,118. This represents 0.03% of its overall portfolio holdings.

Number of Shares
23,036
Previous 22,631 1.79%
Holding current value
$63,118
Previous $76,000 11.84%
% of portfolio
0.03%
Previous 0.04%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.74 - $3.79 $1,109 - $1,534
405 Added 1.79%
23,036 $67,000
Q2 2024

Aug 14, 2024

BUY
$2.31 - $4.99 $17,655 - $38,138
7,643 Added 50.99%
22,631 $76,000
Q1 2024

May 15, 2024

SELL
$2.94 - $4.34 $3,028 - $4,470
-1,030 Reduced 6.43%
14,988 $45,000
Q4 2023

Feb 15, 2024

BUY
$3.96 - $6.41 $24,928 - $40,350
6,295 Added 64.74%
16,018 $67,000
Q3 2023

Nov 07, 2023

SELL
$6.5 - $10.77 $6,298 - $10,436
-969 Reduced 9.06%
9,723 $66,000
Q2 2023

Aug 14, 2023

SELL
$6.69 - $12.25 $22,893 - $41,919
-3,422 Reduced 24.25%
10,692 $111,000
Q1 2023

May 15, 2023

SELL
$6.38 - $12.5 $34,585 - $67,762
-5,421 Reduced 27.75%
14,114 $98,000
Q4 2022

Feb 14, 2023

BUY
$5.75 - $8.5 $67,861 - $100,317
11,802 Added 152.62%
19,535 $117,000
Q3 2022

Nov 14, 2022

BUY
$7.48 - $15.24 $426 - $868
57 Added 0.74%
7,733 $61,000
Q2 2022

Aug 12, 2022

BUY
$13.18 - $19.41 $48,080 - $70,807
3,648 Added 90.57%
7,676 $104,000
Q1 2022

May 16, 2022

SELL
$14.73 - $35.25 $3,387 - $8,107
-230 Reduced 5.4%
4,028 $79,000
Q4 2021

Feb 14, 2022

BUY
$33.72 - $48.22 $71,081 - $101,647
2,108 Added 98.05%
4,258 $146,000
Q3 2021

Nov 15, 2021

SELL
$49.26 - $74.5 $5,369 - $8,120
-109 Reduced 4.83%
2,150 $117,000
Q2 2021

Aug 10, 2021

SELL
$56.91 - $127.53 $12,577 - $28,184
-221 Reduced 8.91%
2,259 $166,000
Q1 2021

May 17, 2021

BUY
$79.79 - $126.29 $3,430 - $5,430
43 Added 1.76%
2,480 $227,000
Q4 2020

Feb 12, 2021

BUY
$46.76 - $136.27 $113,954 - $332,089
2,437 New
2,437 $198,000

Others Institutions Holding CVAC

About CureVac N.V.


  • Ticker CVAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,467,008
  • Market Cap $514M
  • Description
  • CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...
More about CVAC
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.